Personalis sees Q4 revenue approximately $16.7M, consensus $15.33M

Preliminary revenue from biopharma and other customers is estimated to be $15.8 million in the fourth quarter of 2022 compared with $15.4 million in the fourth quarter of 2021, and preliminary revenue from biopharma and other customers includes estimated revenue from Natera at $8.2 million in the fourth quarter of 2022. Interim CEO Aaron Tachibana says: "We ended 2022 by exceeding our previous full year guidance range, driven by oncology revenue growth of 42% for the fiscal year. We will be providing details in the coming weeks about extending our cash runway while focusing on our key product opportunities."